Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients
- 2 February 2012
- journal article
- Published by Informa UK Limited in Gynecological Endocrinology
- Vol. 28 (8), 624-627
- https://doi.org/10.3109/09513590.2011.650752
Abstract
Background: We measured antimullerian hormone (AMH), a marker of ovarian reserve, in women with lupus treated with cyclophosphamide (CYC) (group I), CYC plus gonadotropin-releasing hormone agonist (GnRH-a) (group II) or neither (group III). We hypothesized that AMH would be diminished in women exposed to CYC versus women receiving adjunctive GnRH-a treatment or no CYC exposure. Methods: Forty-eight premenopausal lupus patients were retrospectively divided into three treatment groups: CYC alone (group I, n = 11), CYC + GnRH-a (group II, n = 10) and neither (group III, n = 27). Serum AMH levels between groups were compared using a nonparametric test (Wilcoxon rank-sum). Multiple linear regression adjusting for age was performed. Results: AMH (ng/mL) levels at the last collection were significantly lower in group I versus group III (mean ± SD: 0.18 ± 0.20 group I vs 1.33 ± 1.59 group III; p = 0.015), and versus group II (mean ± SD: 0.86 ± 1.06; p = 0.018). When centered on age 30 years, average AMH levels for group I, group II and group III were 0.20, 0.44 and 1.00, respectively. When adjusted for age, AMH between all groups was significantly different (pConclusion: Posttreatment AMH levels were significantly higher among patients receiving CYC + GnRH-a compared to CYC alone, suggesting that GnRH-a coadministration mitigates CYC-induced ovarian injury.Keywords
This publication has 31 references indexed in Scilit:
- Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trialBreast Cancer Research and Treatment, 2009
- RETRACTED: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized studyFertility and Sterility, 2008
- Use of a gonadotropin‐releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupusArthritis & Rheumatism, 2005
- Preservation of Fertility and Ovarian Function and Minimization of Chemotherapy-Induced Gonadotoxicity in Young Women by GnRH-aJNCI Monographs, 2005
- Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosusLupus, 2004
- Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapyLupus, 2000
- Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapyArthritis & Rheumatism, 1998
- Endocrinology: Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapyHuman Reproduction, 1996
- Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide TherapyAnnals of Internal Medicine, 1993
- Cyclophosphamide-Induced Ovarian FailureNew England Journal of Medicine, 1973